Related Experiment Video

Updated: Mar 2, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Exploiting Epigenetic Alterations in Prostate Cancer

Simon J Baumgart1, Bernard Haendler2

  • 1Drug Discovery, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany. simon.baumgart@bayer.com.

International Journal of Molecular Sciences
|May 10, 2017
PubMed

Insights

Epigenetic alterations in prostate cancer are being targeted by new therapies. Researchers are exploring epigenetic modulators and microRNAs for diagnosis and treatment of this widespread cancer.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Prostate cancer is a significant global health concern, causing numerous cancer-related deaths.
  • Epigenetic alterations, including DNA and histone modifications, are prevalent in prostate tumors.
  • Aberrant enzyme and reader protein activity drives these epigenetic changes, necessitating targeted inhibitors.

Purpose of the Study:

  • To review the role of epigenetic alterations in prostate cancer.
  • To discuss the development and clinical testing of epigenetic modulators.
  • To explore microRNAs as biomarkers and therapeutic agents for prostate cancer.

Main Methods:

  • Review of preclinical and clinical studies on epigenetic modulators in prostate cancer.
  • Analysis of research on microRNAs in prostate cancer diagnosis and treatment.
  • Discussion of current clinical trials involving epigenetic therapies.

Main Results:

  • Epigenetic modulators show promising anti-tumor efficacy in preclinical prostate cancer models.
  • Clinical trials are actively evaluating various epigenetic targets in prostate cancer patients.
  • MicroRNAs are being assessed as potential stratification biomarkers and therapeutic agents.

Conclusions:

  • Epigenetic modifications represent a critical area for prostate cancer research and therapeutic development.
  • Targeting epigenetic pathways offers a promising strategy for novel prostate cancer treatments.
  • MicroRNAs hold potential for improving prostate cancer patient stratification and treatment outcomes.
Keywords:
androgen receptorepigeneticshistonemicroRNAprostate cancer

More Related Videos

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

13.9K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K